Publication | Open Access

PD-L1 testing using the clone 22C3 pharmDx kit for selection of patients with non–small cell lung cancer to receive immune checkpoint inhibitor therapy: are cytology cell blocks a viable option?

Cancer ImmunosurveillanceClone 22C3Cell Lung CancerMedicineImmunologyTumor ImmunityPathologyImmune SurveillancePharmdx KitImmune Checkpoint InhibitorCancer TreatmentImmunotherapyOncologyLung Cancer